Monitoring skeletal response to estrogen

Richard B. Mazess, John Christopher G. Gallagher, Morris Notelovitz, Isaac Schiff, Wulf Utian

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Estrogen replacement therapy at accepted doses is not fully effective in preventing bone loss and fractures in postmenopausal women. Bone densitometry is useful for monitoring estrogen replacement therapy to assess dose, foster compliance, and check for secondary bone loss. The most appropriate site for bone loss monitoring is probably the spine because it shows larger decreases at the menopause than appendicular sites, it shows larger increases with therapy, and it has clinical import in terms of fracture. Both dual-photon absorptiometry (or dual-energy x-ray absorptiometry) and computed tomography are the preferred monitoring methods. The precision of these densitometry methods is generally adequate to permit interim decisions with regard to continuing therapy, as well as conclusive decisions on therapeutic efficacy after 1 to 2 years of monitoring. Judicious use of densitometry in combination with biochemical determinations can enhance therapeutic control and provide both patient and physician confidence in long-term estrogen replacement therapy.

Original languageEnglish
Pages (from-to)843-848
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume161
Issue number4
DOIs
StatePublished - 1989

Fingerprint

Estrogen Replacement Therapy
Densitometry
Estrogens
Bone and Bones
Bone Fractures
Photon Absorptiometry
Therapeutics
Menopause
Compliance
Spine
Tomography
X-Rays
Physicians

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Monitoring skeletal response to estrogen. / Mazess, Richard B.; Gallagher, John Christopher G.; Notelovitz, Morris; Schiff, Isaac; Utian, Wulf.

In: American Journal of Obstetrics and Gynecology, Vol. 161, No. 4, 1989, p. 843-848.

Research output: Contribution to journalArticle

Mazess, Richard B. ; Gallagher, John Christopher G. ; Notelovitz, Morris ; Schiff, Isaac ; Utian, Wulf. / Monitoring skeletal response to estrogen. In: American Journal of Obstetrics and Gynecology. 1989 ; Vol. 161, No. 4. pp. 843-848.
@article{c3ac9d05795f4dfbae66ed42adbc0999,
title = "Monitoring skeletal response to estrogen",
abstract = "Estrogen replacement therapy at accepted doses is not fully effective in preventing bone loss and fractures in postmenopausal women. Bone densitometry is useful for monitoring estrogen replacement therapy to assess dose, foster compliance, and check for secondary bone loss. The most appropriate site for bone loss monitoring is probably the spine because it shows larger decreases at the menopause than appendicular sites, it shows larger increases with therapy, and it has clinical import in terms of fracture. Both dual-photon absorptiometry (or dual-energy x-ray absorptiometry) and computed tomography are the preferred monitoring methods. The precision of these densitometry methods is generally adequate to permit interim decisions with regard to continuing therapy, as well as conclusive decisions on therapeutic efficacy after 1 to 2 years of monitoring. Judicious use of densitometry in combination with biochemical determinations can enhance therapeutic control and provide both patient and physician confidence in long-term estrogen replacement therapy.",
author = "Mazess, {Richard B.} and Gallagher, {John Christopher G.} and Morris Notelovitz and Isaac Schiff and Wulf Utian",
year = "1989",
doi = "10.1016/0002-9378(89)90732-1",
language = "English",
volume = "161",
pages = "843--848",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Monitoring skeletal response to estrogen

AU - Mazess, Richard B.

AU - Gallagher, John Christopher G.

AU - Notelovitz, Morris

AU - Schiff, Isaac

AU - Utian, Wulf

PY - 1989

Y1 - 1989

N2 - Estrogen replacement therapy at accepted doses is not fully effective in preventing bone loss and fractures in postmenopausal women. Bone densitometry is useful for monitoring estrogen replacement therapy to assess dose, foster compliance, and check for secondary bone loss. The most appropriate site for bone loss monitoring is probably the spine because it shows larger decreases at the menopause than appendicular sites, it shows larger increases with therapy, and it has clinical import in terms of fracture. Both dual-photon absorptiometry (or dual-energy x-ray absorptiometry) and computed tomography are the preferred monitoring methods. The precision of these densitometry methods is generally adequate to permit interim decisions with regard to continuing therapy, as well as conclusive decisions on therapeutic efficacy after 1 to 2 years of monitoring. Judicious use of densitometry in combination with biochemical determinations can enhance therapeutic control and provide both patient and physician confidence in long-term estrogen replacement therapy.

AB - Estrogen replacement therapy at accepted doses is not fully effective in preventing bone loss and fractures in postmenopausal women. Bone densitometry is useful for monitoring estrogen replacement therapy to assess dose, foster compliance, and check for secondary bone loss. The most appropriate site for bone loss monitoring is probably the spine because it shows larger decreases at the menopause than appendicular sites, it shows larger increases with therapy, and it has clinical import in terms of fracture. Both dual-photon absorptiometry (or dual-energy x-ray absorptiometry) and computed tomography are the preferred monitoring methods. The precision of these densitometry methods is generally adequate to permit interim decisions with regard to continuing therapy, as well as conclusive decisions on therapeutic efficacy after 1 to 2 years of monitoring. Judicious use of densitometry in combination with biochemical determinations can enhance therapeutic control and provide both patient and physician confidence in long-term estrogen replacement therapy.

UR - http://www.scopus.com/inward/record.url?scp=0024452063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024452063&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(89)90732-1

DO - 10.1016/0002-9378(89)90732-1

M3 - Article

C2 - 2679103

AN - SCOPUS:0024452063

VL - 161

SP - 843

EP - 848

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 4

ER -